2024
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
Ren J, Liao X, Lewis J, Chang J, Qu R, Carlson K, Foss F, Girardi M. Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy. Nature Communications 2024, 15: 519. PMID: 38225288, PMCID: PMC10789731, DOI: 10.1038/s41467-024-44786-2.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityDonor T cellsT cellsAdeno-associated virus transductionHealthy donor T cellsHost-versus-graft reactivityEnhanced antibody-dependent cellular cytotoxicityCAR-T cellsGraft-versus-hostT cell killingT-cell malignanciesMalignant T cellsNormal T-cellT cell receptorOff-target toxicityPre-existing immunoreactivityCAR-TDisease relapseCellular cytotoxicityVirus transductionCurrent treatmentPersister killingFc engineeringB2MIn vivo
2022
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma
Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaBone marrow involvementBlood involvementFlow cytometryMarrow involvementNodal subtypesAggressive peripheral T-cell lymphomaNodal T-cell lymphomasNegative flow cytometryPeripheral blood involvementPositive flow cytometryMalignant T cellsMalignant tumor cellsMedian PFSTime ofdiagnosisOverall survivalLymph nodesPoor outcomeDisease stagePeripheral bloodT cellsPrognostic measuresRare subgroupLymphoma
2017
Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma
Fanok MH, Sun A, Fogli LK, Narendran V, Eckstein M, Kannan K, Dolgalev I, Lazaris C, Heguy A, Laird ME, Sundrud MS, Liu C, Kutok J, Lacruz RS, Latkowski JA, Aifantis I, Ødum N, Hymes KB, Goel S, Koralov SB. Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma. Journal Of Investigative Dermatology 2017, 138: 1116-1125. PMID: 29128259, PMCID: PMC5912980, DOI: 10.1016/j.jid.2017.10.028.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaHigh-throughput transcriptional profilingJAK/STATT cell receptor engagementT cellsGenetic perturbationsTranscriptome analysisTranscriptional profilingConditional geneDeep sequencingCytokine signalingTumor genomesMalignant T cellsCellular etiologyHeterogeneous landscapesReceptor engagementSmall animal modelsCommon variantsMycosis fungoidesKey cytokineAntigenic stimulationT lymphocytesLymphoma pathogenesisMouse model
2010
Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma
Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Management And Research 2010, 2: 53-59. PMID: 21188096, PMCID: PMC3004568, DOI: 10.2147/cmar.s5009.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaTreatment of patientsT-cell lymphomaDenileukin diftitoxFusion protein toxinsT cellsCytocidal agentsRare lymphoproliferative disorderPivotal clinical trialsMalignant T cellsBiological response modifiersQuality of lifeMechanism of actionCD25 subunitCommon toxicitiesProgressive lymphomaLymphoproliferative disordersClinical trialsResponse modifiersIL2 receptorTraditional chemotherapyDiftitoxB cellsFDA approvalCurrent and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma
Lansigan F, Foss FM. Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma. Drugs 2010, 70: 273-286. PMID: 20166766, DOI: 10.2165/11532190-000000000-00000.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaMalignant T cellsTreatment strategiesT cellsManagement of CTCLPredictable adverse effectsRapid disease controlConservative treatment strategyFront-line therapyEarly-stage diseaseIndolent clinical courseMature T-cell lymphomasStem cell transplantInterleukin-2 receptorHistone deacetylase inhibitorsSystemic chemotherapyExtracorporeal photopheresisInitial managementSézary syndromeClinical courseCurative therapyBiological therapyCell transplantMycosis fungoides
2008
Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL)
Alpdogan O, Ornstein D, Subtil T, Seropian S, Cooper D, Foss F. Outcomes in Subcutaneous Panniculitis-Like T-Cell Lymphoma (STCL). Blood 2008, 112: 3750. DOI: 10.1182/blood.v112.11.3750.3750.Peer-Reviewed Original ResearchSubcutaneous panniculitis-like T-cell lymphomaPanniculitis-like T-cell lymphomaTCR gene rearrangementsT-cell lymphomaRetrospective studyDenileukin diftitoxPoor prognosisT cellsCytotoxic T-cell markersAllogeneic hematopoietic stem cellsT cell receptor expressionCytotoxic chemotherapy regimensMatched-related donorsEvidence of diseaseRare clinical entityAggressive clinical courseT-cell markersMalignant T cellsCell receptor expressionClonal TCR gene rearrangementNovel T cellAllogeneic HSCTMedian followAggressive therapyChemotherapy regimens
2002
Efficient Tumor Antigen Loading of Dendritic Antigen Presenting Cells by Transimmunization
Girardi M, Berger C, Hanlon D, Edelson RL. Efficient Tumor Antigen Loading of Dendritic Antigen Presenting Cells by Transimmunization. Technology In Cancer Research & Treatment 2002, 1: 65-69. PMID: 12614179, DOI: 10.1177/153303460200100109.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMalignant T cellsT cellsTumor antigen loadingAnti-tumor immunityManagement of patientsT-cell lymphomaAntigen presenting cellsDendritic cell differentiationDendritic cellsSelective immunotherapyPresenting cellsOnly FDATumor antigensCell lymphomaAntigen loadingTumor cellsKey cellular eventsTransimmunizationImmunotherapyPatientsCancerRecent findingsEfficient phagocytosisCells
2001
Induction of human tumor‐loaded dendritic cells
Berger C, Xu A, Hanlon D, Lee C, Schechner J, Glusac E, Christensen I, Snyder E, Holloway V, Tigelaar R, Edelson R. Induction of human tumor‐loaded dendritic cells. International Journal Of Cancer 2001, 91: 438-447. PMID: 11251964, DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1073>3.0.co;2-r.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, CDApoptosisCD36 AntigensCell DifferentiationCell DivisionCell SurvivalCells, CulturedCytokinesCytoplasmDendritic CellsDose-Response Relationship, DrugFlow CytometryHumansImmunoglobulinsImmunohistochemistryImmunophenotypingImmunotherapyLeukapheresisLeukocytesLymphocytesMajor Histocompatibility ComplexMembrane GlycoproteinsMonocytesPhagocytosisPhenotypeTime FactorsT-LymphocytesConceptsExtracorporeal photopheresisDistinctive antigensTumor-loaded dendritic cellsStandard extracorporeal photopheresisMHC class II moleculesImproved cancer immunotherapyDendritic cell differentiationAnti-cancer vaccinesMalignant T cellsClass II moleculesTransition of monocytesDC vaccinesMalignant cell apoptosisDendritic cellsImmature DCsCancer immunotherapyCD83 expressionT cellsExogenous cytokinesSignificant proliferationCell apoptosisVaccineMembrane CD36Cell differentiationCells
1998
Tumor‐specific peptides in cutaneous T‐cell lymphoma: Association with class I major histocompatibility complex and possible derivation from the clonotypic T‐cell receptor
Berger C, Longley B, Imaeda S, Christensen I, Heald P, Edelson R. Tumor‐specific peptides in cutaneous T‐cell lymphoma: Association with class I major histocompatibility complex and possible derivation from the clonotypic T‐cell receptor. International Journal Of Cancer 1998, 76: 304-311. PMID: 9579563, DOI: 10.1002/(sici)1097-0215(19980504)76:3<304::aid-ijc3>3.0.co;2-z.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAntigens, NeoplasmCD8-Positive T-LymphocytesGenes, T-Cell Receptor betaHistocompatibility Antigens Class IHumansLymphoma, T-Cell, CutaneousMolecular Sequence DataPeptidesProtein ConformationSequence AlignmentSequence Homology, Amino AcidSkin NeoplasmsT-Lymphocyte SubsetsT-Lymphocytes, CytotoxicTumor Necrosis Factor-alphaConceptsCutaneous T-cell lymphomaT cell receptorClonotypic T cell receptorIdiotypic peptideT-cell lymphomaCD8 cellsClass I moleculesCTCL patientsClass I peptidesTumor cellsClass II moleculesAnti-tumor vaccinesClass I major histocompatibilityMalignant T cellsCTCL tumor cellsTumor-specific peptidesI peptidesTNF-alpha assayCD8 responsesNovel class IPeptide-binding motifTumor necrosisT cellsCTCL cells
1987
Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis.
Dmitrovsky E, Matthews M, Bunn P, Schechter G, Makuch R, Winkler C, Eddy J, Sausville E, Ihde D. Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis. Journal Of Clinical Oncology 1987, 5: 208-15. PMID: 3492594, DOI: 10.1200/jco.1987.5.2.208.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaCytologic transformationCell lymphomaClinical courseClinicopathologic entityCutaneous T-cell lymphoma patientsTumor cell DNA contentT-cell lymphoma patientsAggressive clinical courseDistinct clinicopathologic entityCell lymphoma patientsPeripheral blood smearMalignant T cellsLarge cell lymphomaConvoluted lymphocytesMedian survivalVisceral sitesLymph nodesOccasional patientMedian timeLymphoma patientsPoor prognosisCell DNA contentT cells
1984
The Intracutaneous Growth of Murine Lymphomas: Epidermal Invasion Is Characteristic of Multiple Tumor Phenotypes
Piepkorn M, Tigelaar R. The Intracutaneous Growth of Murine Lymphomas: Epidermal Invasion Is Characteristic of Multiple Tumor Phenotypes. Journal Of Investigative Dermatology 1984, 83: 281-285. PMID: 6237158, DOI: 10.1111/1523-1747.ep12340368.Peer-Reviewed Original ResearchConceptsMycosis fungoidesT cellsHelper/inducer T cellsCutaneous T-cell lymphomaT cell surface phenotypeInducer T cellsBALB/c originT-cell lymphomaMalignant T cellsLymphoid cell subsetsEosin-stained sectionsCenter of tumorT cell linesCytotoxic markersSézary syndromeCell subsetsBenign dermatosesDermal-epidermal junctionEpidermal necrosisParallel groupIntradermal injectionT lymphocytesSyngeneic miceSurface phenotypeLymphoid cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply